9 results about "Islet cells" patented technology

The present application discloses the use of SUR2 receptor modulators. In the present application, SUR2 receptor modulators (e.g. MLC1) can be combined with skeletal muscle cell K ATP SUR2 specific binding on potassium ion channel, thus enhancing intracellular calcium signal, increasing glucose uptake of skeletal muscle cell and reducing blood glucose, and thus can be used as a therapeutic drug for diabetes; SUR2 receptor modulators selectively bind to SUR2 through a non-islet β cell dependent mechanism, and have no inhibitory effect on islet β cell SUR1 receptor, and thus can effectively avoid hypoglycemia while reducing blood glucose, and have small side effects.

The application discloses a sea cucumber active peptide, a preparation method and a blood glucose reduction application, belongs to the field of biological medicines, and the amino acid sequence of the active peptide is Thr-Ser-Pro-Gly-Leu-Gly-Lys-Gly-Phe. The preparation method comprises the following steps: putting chopped sea cucumbers into a reaction container, adding a compound protease for enzyme hydrolysis; enzyme inactivation and centrifugation are performed, and the supernatant is taken; the supernatant is subjected to ultrafiltration through an ultrafiltration membrane with a molecular weight cut-off of 1000 Da, the obtained filtrate is dried to obtain a sea cucumber oligopeptide powder, and Sephadex G25F gel chromatography column separation and purification and C18 reverse phase chromatography column further purification are performed. Experiments show that the active peptide can relieve STZ-induced pancreatic beta cell damage.

The application provides a construction method of a zebrafish model of diabetic cerebral hemorrhage sequelae for high-throughput drug screening, and belongs to the technical field of biotechnology.The first zebrafish model capable of comprehensively simulating the complex pathological phenotypes of clinical diabetic cerebral hemorrhage sequelae is successfully constructed, and the blank of the research model in the field is filled.The pathological changes of the model are highly consistent with the symptoms of the patients with clinical diabetic cerebral hemorrhage sequelae, such as glucose metabolism disorder, pancreatic beta cell damage, cerebral vascular injury and hemorrhage, brain cell apoptosis, inflammatory reaction and behavior abnormality, and the limitation that the existing single disease model cannot simulate the synergistic pathogenesis of diabetes and cerebral hemorrhage is overcome, so that a reliable experimental animal model is provided for high-throughput screening of active ingredients against the disease.

Provided herein are methods of dosing engineered islet cells that include functional modified beta cell containing one or more modifications, such as genetic modifications. In some embodiments, the engineered islets are hypoimmunogenic cells. In some embodiments, the one or more modifications reduce or eliminate expression of one or more MHC class I and / or MHC class II human leukocyte antigens and also increase expression of one or more tolerogenic factors, such as CD47. In some embodiments, the subject has a beta cell related disorder, such as diabetes (e.g. Type I diabetes).

The application relates to the technical field of biological pharmacy, in particular to application of recombinant protein DEL-1 in preparation of a drug for improving insulin secretion function of human islets. The application finds that the recombinant protein DEL-1 has a significant improvement effect on insulin secretion dysfunction in various human islet injury models. Experiments show that in a high-sugar combined palmitic acid injury model and an inflammatory cytokine injury model, DEL-1 can significantly improve the insulin secretion function of human islets. Specifically, compared with an injury group, after DEL-1 treatment, the glucose stimulation index of human islets and the relative secretion amount of insulin under high-sugar stimulation are both significantly increased, which proves that DEL-1 has a clear effect of promoting insulin secretion function of human islet beta cells.

The application discloses an injectable hydrogel of islet-like spheroids based on double sequential encapsulation and a preparation and application thereof, and belongs to the technical field of bioengineering medical materials. The preparation method utilizes the positive and negative charges of a polymer material, forms an immune protection film of islet beta cells through electrostatic adsorption layer-by-layer self-assembly, and utilizes the extracellular matrix of a spleen, i.e., the characteristics of a liquid state in vitro and self-assembly into a nanofiber gel structure at a physiological temperature in vivo, to prepare the injectable hydrogel of islet-like spheroids, so as to ensure the stability of the hydrogel structure, self-assembly into a nanofiber three-dimensional gel structure in vivo, provide a natural specific microenvironment for cell self-renewal and differentiation, promote the aggregation of beta cells into islet-like spheroids, and enhance the insulin secretion and vascularization capacity. The immune protection film is formed on the surface of the islet beta cells through layer-by-layer self-assembly of gelatin and alginate, so that the beta cell immune protection encapsulation is realized.

This invention discloses a composition for the prevention or treatment of diabetes and its application, relating to the field of pharmaceutical technology. The composition is a combination of any of the following components: a mitochondrial protectant, a vanadium compound, and a hormone / pheromone. It can improve pancreatic β-cell activity and control fasting blood glucose, satiety blood glucose, glucose tolerance, and insulin levels within dietary dosage ranges.

This invention relates to the field of islet transplantation technology, specifically disclosing methods for promoting... GPX3 The application of the expressed product in the preparation of drugs that inhibit early ferroptosis in transplanted pancreatic islets. The present invention provides a promoting... GPX3 The expressed product is used to inhibit early ferroptosis in transplanted islets, improve the survival rate of transplanted islets, and maintain the activity of transplanted islet cells.